Open main menu

Psychiatrienet β

Paroxetine-venlafaxine

Revision as of 15:51, 21 October 2015 by Anoek (talk | contribs)
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from paroxetine to venlafaxine.[1] [2]

Nietinrijdenbord.png Stop paroxetine
  • Day -7: reduce dosage of paroxetine to 20 mg/day, if this dosage is > 20 mg/day.
  • Day 0: dosage of paroxetine is 20 mg/day.
  • Day 1: reduce dosage of paroxetine to 10 mg/day.
  • Day 8: reduce dosage of paroxetine to 5 mg/day.
  • Day 15: stop administration of paroxetine.
Eenrichtingbord.png Start venlafaxine
  • No wash-out period is needed.
  • Start administration of venlafaxine in a normal dosage of 37,5 mg or 75 mg (slow release) /day.
Infobord.png More information
  • Occurrence of the serotonin syndrome is theoretically possible.
  • Paroxetine slows the metabolism of venlafaxine via CYP2D6.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.